| Oxalic Diamides and tert-Butoxide: Two Types of Ligands Enabling Practical Access to Alkyl Aryl Ethers via Cu-Catalyzed Coupling Reaction Z Chen, Y Jiang, L Zhang, Y Guo, D Ma Journal of the American Chemical Society 141 (8), 3541-3549, 2019 | 146 | 2019 |
| Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect H Cao, ZX Chen, K Wang, MM Ning, QA Zou, Y Feng, YL Ye, Y Leng, ... Scientific reports 6 (1), 28676, 2016 | 53 | 2016 |
| Cu/N,N′-Dibenzyloxalamide-Catalyzed N-Arylation of Heteroanilines Z Chen, D Ma Organic letters 21 (17), 6874-6878, 2019 | 41 | 2019 |
| Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity Z Chen, B Hu, RK Rej, D Wu, RK Acharyya, M Wang, T Xu, J Lu, ... Journal of Medicinal Chemistry 66 (17), 12559-12585, 2023 | 9 | 2023 |
| Discovery and structure–activity relationship study of 4-phenoxythiazol-5-carboxamides as highly potent TGR5 agonists Z Chen, M Ning, Q Zou, H Cao, Y Ye, Y Leng, J Shen Chemical and Pharmaceutical Bulletin 64 (4), 326-339, 2016 | 6 | 2016 |
| Discovery of CBPD-268 as an exceptionally potent and orally efficacious CBP/p300 PROTAC degrader capable of achieving tumor regression Z Chen, M Wang, D Wu, L Bai, T Xu, H Metwally, Y Wang, D McEachern, ... Journal of Medicinal Chemistry 67 (7), 5275-5304, 2024 | 4 | 2024 |
| Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer Z Chen, M Wang, D Wu, L Zhao, H Metwally, W Jiang, Y Wang, L Bai, ... Journal of Medicinal Chemistry 67 (7), 5351-5372, 2024 | 3 | 2024 |
| p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer BioRxiv, 2024 | 1 | 2024 |
| SMALL MOLECULE DEGRADERS OF ESTROGEN RECEPTOR WITH CEREBLON LIGANDS S Wang, Z Chen, R Rej, D Wu, J Lu, B Hu, M Wang, RK Acharyya US Patent App. 18/279,236, 2024 | | 2024 |
| Cereblon Ligands S Wang, T Xu, D Wu, Z Chen, X Han, W Xiang, R Rej, A Aguilar, L Bai US Patent App. 18/279,225, 2024 | | 2024 |
| Small Molecule Degraders of CBP/p300 Proteins S Wang, Z Chen, D Wu, M Wang US Patent App. 18/279,232, 2024 | | 2024 |
| Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p300 PROTAC degraders for the treatment of castration-resistant prostate cancer Z Chen, M Wang, D Wu, L Zhao, T Xu, H Metwally, Y Wang, D McEachern, ... Cancer Research 84 (6_Supplement), 4504-4504, 2024 | | 2024 |
| The selective IKZF2 molecular glue degrader, PVTX-405, counters Treg immune suppression, shows significant tumor growth delay as single agent and synergistic response with … HD Dhruv, D McEachern, L Bai, X Zhang, Z Chen, R Nagilla, E Behshad, ... Cancer Research 84 (6_Supplement), 2656-2656, 2024 | | 2024 |
| Potent and orally efficacious PROTAC degraders of estrogen receptor α (ERα) RK Rej, Z Chen, RK Acharyya, D Wu, B Hu, G Xu, R Nagilla, H Metwally, ... Cancer Research 84 (6_Supplement), 4510-4510, 2024 | | 2024 |
| Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader J luo, A Prolia, Y Qiao, J Tian, R Mannan, S Mahapatra, Z Chen, R Seri, ... Cancer Research 84 (6_Supplement), 6048-6048, 2024 | | 2024 |
| Cereblon Ligands and Uses Thereof S Wang, Z Chen, D Wu, YM Siu, R Rej, RK Acharyya, W Xiang, L Bai US Patent App. 18/220,959, 2024 | | 2024 |
| Cereblon Ligands and Uses Thereof S Wang, Z Chen, D Wu, RK Acharyya, W Xiang, R Rej, L Bai, X Zhang, ... US Patent App. 18/221,005, 2024 | | 2024 |
| Cereblon ligands and uses thereof R Rej, Z Chen, L Bai, RK Acharyya, D Wu, P Kirchhoff, Z Li | | 2024 |
| Indole derivatives as estrogen receptor degraders and their preparation Z Chen, M Wang, D Wu, G Xu, RK Acharyya, B Hu, J Lu, S Wang | | 2024 |
| Chroman derivatives as estrogen receptor degraders and their preparation G Xu, RK Acharyya, R Rej, Z Chen, B Hu, J Lu, S Wang | | 2024 |
